Trademarkia Logo

Canada

C$
Trademark Search in Canada
IMMUVANCE

View On IC.GC.CA

IMMUVANCE
WITHDRAWN BY OWNER

on 29 Jun 2022

TM5 Status

DEAD/APPLICATION/ Withdrawn/Abandoned

Your application has been withdrawn or abandoned. You cannot use the TM5 mark.

Last Applicant/ Owned by

CYTODYN INC.

Suite 660,1111 Main StreetVancouver WA 98660

US

Serial Number

2049382 filed on 26th Jun 2020

Correspondent Address

SMART & BIGGAR LP

SCOTIA PLAZA40 KING STREET WEST40th FLOORTORONTO

ONTARIO

CA

M5H3Y2

IMMUVANCE

Trademark usage description

therapeutic preparations, namely, antibodies for use in targeting the c-c chemokine receptor type 5 [ccr5] cell receptor; therapeutic preparations for Read More

Classification Information

Class [005]
Therapeutic preparations, namely, antibodies for use in targeting the C-C chemokine receptor type 5 [CCR5] cell receptor; therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, non-alcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, non-alcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19.

Classification kind code

11

Class [042]
Scientific research consulting services in the field of immunology; scientific research consulting services in the field of antibodies for use in targeting the CCR5 cell receptor; scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor; medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the foregoing excluding medical research and scientific research consulting services directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting.

Classification kind code

11

Class [044]
Providing medical information, via a website; providing information in the field of using antibodies for medical treatment, for use in targeting the CCR5 cell receptor, via a website; providing health and medical information, via a website, namely, providing information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the forgoing excluding information directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting.

Classification kind code

11

Mark Details

Serial Number

2049382

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 22
on 6th Jan 2022		Search Recorded
Submitted for opposition 20
on 6th Jan 2022		Examiner's First Report
Submitted for opposition 223
on 6th Jan 2022		Total Provisional Refusal
Submitted for opposition 256
on 5th Jul 2021		Notification of Possible Opposition Sent
Submitted for opposition 48
on 22nd Jun 2021		Agent Changed
Submitted for opposition 257
on 3rd Sept 2020		Designation Notification - Madrid Protocol
Submitted for opposition 31
on 2th Sept 2020		Formalized
Submitted for opposition 1
on 2th Sept 2020		Created
Submitted for opposition 228
on 26th Jun 2020		International Registration
Submitted for opposition 30
on 26th Jun 2020		Filed